Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 15/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | QPCT | Q16769 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3491066 | 0.85 | GSK3B (0.59) | GSK3BQPCTNPC1ALDH1A1HPGD | |
| SCHEMBL3493258 | 0.83 | GSK3B (0.52) | GSK3BSMN1; SMN2TP53NPC1ALDH1A1 | |
| SCHEMBL3491248 | 0.83 | GSK3B (0.65) | GSK3B | |
| SCHEMBL3492412 | 0.82 | GSK3B (0.52) | GSK3BSMN1; SMN2TP53NPC1ALDH1A1 | |
| SCHEMBL3491944 | 0.81 | GSK3B (0.63) | GSK3B | |
| SCHEMBL3492985 | 0.80 | GSK3B (0.62) | GSK3B | |
| SCHEMBL3492038 | 0.78 | GSK3B (0.68) | GSK3B | |
| SCHEMBL3491150 | 0.78 | CREBBP (0.49) | GSK3BSMN1; SMN2TP53NPC1ALDH1A1 | |
| SCHEMBL3490534 | 0.77 | GSK3B (0.72) | GSK3BNPC1 | |
| SCHEMBL3491459 | 0.76 | GSK3B (0.67) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492378-B2 | GSK-3β inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069381-A1 | GSK-3BETAINHIBITOR | GSK3B, GSK3A, GSKIP | GSK3B 1/4885SMN1; SMN2 1036/4885TP53 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.